

# **DIVA Investor Conference**

DIA Labs.

#### **Participants**

Vice Chairman & CEO

Gene Chen

GM

Yvonne Liu

Admin VP & Spokesman

Michael Mai

Finance Senior Manager

**Angel Chiang** 



#### **Agenda**

—. Company Profile

二. 2024 Q1-Q3 Financial Results

三. Business Update and Outlook

四. Q&A

Admin VP & Spokesman

Michael Mai

GM

Yvonne Liu

Vice Chairman & CEO

Gene Chen



#### **Safe Harbor Notice**

We have made forward-looking statements in the presentation. Our forward- looking statements contain information regarding, among other things, our financial conditions, future expansion plans and business strategies. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that these expectations and projections are reasonable, such forward-looking statements are inherently subject to risks, uncertainties, and assumptions about us.

We undertake no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events might not occur and our actual results could differ materially from those anticipated in these forward-looking statements.





# —.Company Profile

Admin VP & Spokesman Michael Mai



#### **DIVA Labs.**

Focused on providing high quality precision displays to meet the product requirements of global OEM and ODM customers

Year Established 1995

IPO Year 2013

(Ticker 4153)

Capital (NTD) 601M

No. of Employees 145+

#### **Global Presence**

Manufacturing Sites: Taiwan

Sales Offices: 3 Locations Worldwide

R&D: Taiwan

Revenue Breakdown by Geography:

	2022	2023	2024
<b>Americas</b>	43%	37%	44%
Europe	39%	44%	39%
Taiwan	8%	6%	5%
Others	10%	13%	12%

2024 Q1-Q3 Revenue

NTD\$ 639M (USD\$ 20M)

2023 Revenue

NTD\$ 894M (USD\$28.8M)





#### 二. 2024 Q1~Q3 Financial Results

Admin VP & Spokesman Michael Mai



#### 2024 Q1-Q3 Highlights



#### **Revenue -7% YoY in the first three quarters**

• -1% for medical, -4% for industrial, and -2% for parts and components.

# 02

# Operating income and net income attributable to the parent company YoY in the first three quarters

 Operating income +21%, and net income attributable to the parent company +34%.

#### **Consolidated Statement of Comprehensive Income(Quarterly)**

Unit: NT\$Million

Net Sales
Cost of Goods Sold
Gross Margin
Operating Expenses
Operating Income
Net non-operating Income
Profit(Loss) before Tax
Net Income
Net income attributable to DIVA
EPS (NT\$) (a)

	2024 Q3						
•	194	100%					
	(135)						
	59	30%					
	(39)	-20%					
	20	10%					
	0						
	20	10%					
	15	8%					
	15	8%					
	\$0.26						

2023 Q3					
207	100%				
(146)					
62	30%				
(35)	-17%				
26	13%				
(1)					
25	12%				
19	9%				
19	9%				
\$0.33					

YoY						
amt	g%					
(14)	-7%					
11						
(3)	-4%					
(4)						
(7)	-25%					
1						
(5)	-21%					
(4)	-22%					
(4)	-22%					
-\$0.07						

2024 Q2						
223	100%					
(152)						
71	32%					
(40)	-18%					
31	14%					
1						
32	14%					
31	14%					
31	14%					
\$0.52						

QoQ						
amt	g%					
(29)	-13%					
17						
(12)	-17%					
1						
(12)	-37%					
(1)						
(12)	-38%					
(16)	-51%					
(16)	-51%					
-\$0.26						

(a) EPS was calculated based on total weighted-averaged outstanding shares



#### **Consolidated Statement of Comprehensive Income (YTD)**

Unit: NT\$Million

Net Sales
Cost of Goods Sold
Gross Margin
Operating Expenses
Operating Income
Net non-operating Income
Profit(Loss) before Tax
Net Income
Net income attributable to DIVA
EPS (NT\$) (a)

2024 Q3						
639	100%					
(447)						
193	30%					
(111)	-17%					
81	13%					
3						
84	13%					
70	11%					
70	11%					
\$1.20						

2023 Q3					
689	100%				
(485)					
204	30%				
(137)	-20%				
67	10%				
(6)					
61	9%				
53	8%				
53	8%				
\$0.90					


YoY				
amt	g%			
(50)	-7%			
39				
(11)	-6%			
26				
14	21%			
9				
23	38%			
18	34%			
18	34%			
\$0.30				

(a) EPS was calculated based on total weighted-averaged outstanding shares




#### **Revenue and Operating Income**

**Unit: NT\$ Million** 



**Unit: NT\$ Million** 



Revenue

**Operating Income** 




## **Consolidated Balance Sheet Highlights**

Unit: NT\$ Million	2024 00	2024.09.30		2024.06.30		οQ	2023.09.30		YoY	
	2024.09	.50	2024.00	.50	amt	g%	2023.09.30		amt	g%
Cash & Equivalent	546	44%	608	45%	-61	-10%	460	38%	87	19%
Accounts Receivable	233	19%	251	19%	-18	-7%	241	20%	-8	-3%
Inventory	175	14%	179	13%	-4	-2%	226	18%	-50	-22%
Financial assets at fair value through other comprehensive income-non-current	6	0%	8	1%	-2	-28%	4	0%	1	25%
Total Assets	1,251	100%	1,339	100%	-88	-7%	1,224	100%	27	2%
Fin. Debt	-	0%	1	0%	-1	-100%	2	0%	-2	0%
Accounts Payable	66	5%	84	6%	-18	-21%	64	5%	2	4%
Toal Liabilities	219	18%	319	24%	-100	-31%	211	17%	8	4%
Equity	1,032	82%	1,019	76%	13	1%	1,012	83%	19	2%




#### Consolidated revenue - by product application







#### Consolidated revenue - by sales area



# Consolidated revenue - by customer segment



### Consolidated revenue - by revenue concentration







### 三. Business Update and Outlook

GM Yvonne Liu





# Optimization of <u>existing</u> <u>customer</u> operations

Close to the needs of customers, and jointly develop future models

Lean manufacturing and R&D technology with synergy

Group manufacturing strengths and established development technology capabilities

Major Pillars

# Expanding the <u>market share</u> of medical display

Efforts to develop ODM market for medical display products

#### **Provide total solutions**

Solve customers' problems in various situations of medical display use



#### 2025 Outlook

### Large-size Medical Displays Produced by Suzhou Qisda

- Mass production will officially begin by the end of 2024.
- Revenue contribution is expected to start in early Q2 of 2025.

# Development of New OTS Models

- The cost is competitive in the market.
- The market size is substantial, and successful development will significantly contribute to revenue.





四. Q&A



# Thank you